31-45 of 88
Patient-Centered Insights for Advanced Prostate Cancer Treatment
On the Frontlines of Prostate CancerPatient-Centered Insights for Advanced Prostate Cancer Treatment
Tanya Dorff, MD
Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
On the Frontlines of Prostate CancerAdvances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
Neal Shore, MD, FACS
mCRPC Care: Predicting Outcomes with a Novel Cell-Free DNA Sequencing Assay
On the Frontlines of Prostate CancermCRPC Care: Predicting Outcomes with a Novel Cell-Free DNA Sequencing Assay
Scott Dehm, PhD
Navigating mCRPC Treatment: A Look at Abiraterone and Enzalutamide
Project Oncology®Navigating mCRPC Treatment: A Look at Abiraterone and Enzalutamide
Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
Project Oncology®Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
Charles Turck, PharmD, BCPS, BCCCP
Hannah McManus, MD
Andrew Armstrong, MD, MSc
Understanding the Full Spectrum and Burden of Multi-Food Allergies
On the Frontlines of Food AllergiesUnderstanding the Full Spectrum and Burden of Multi-Food Allergies
Christopher M. Warren, PhD
- advertisement
How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
Project Oncology®How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
Daniel Kwon, MD
Precision Strikes in Nuclear Medicine to Treat Prostate Cancer
Project Oncology®Precision Strikes in Nuclear Medicine to Treat Prostate Cancer
Munir Ghesani, MD
A Look at the Utility of PSMA PET Scans in Prostate Cancer
Project Oncology®A Look at the Utility of PSMA PET Scans in Prostate Cancer
Jennifer Caudle, DO, FACOFP
Geoffrey B. Johnson, M.D., Ph.D.
Salivary Toxicity from PSMA-Targeted Radiopharmaceuticals in mCRPC
Project Oncology®Salivary Toxicity from PSMA-Targeted Radiopharmaceuticals in mCRPC
Geoffrey B. Johnson, M.D., Ph.D.
Disparities in DMT Access: Women with MS Are Less Likely to Receive Treatment
NeuroFrontiersDisparities in DMT Access: Women with MS Are Less Likely to Receive Treatment
Andrew Wilner, MD, FACP, FAAN
Victoria Leavitt, PhD
Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Project Oncology®Treating mCRPC with Lutetium-177 and Radium-223: Expert Insights
Alan Bryce, MD
- advertisement
mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
Project Oncology®mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib
Charles Turck, PharmD, BCPS, BCCCP
Neeraj Agarwal, MD, FASCO
Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
Project Oncology®Prostate Cancer Research: Why Disparities Exist in Mortality and Trial Access
Rishi Sekar, MD
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
Project Oncology®Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
Zachery Reichert MD, PhD
